Biomeme
Portable PCR labs for biothreat detection and point-of-care diagnostics
Website: https://biomeme.com/
Cover Block
PUBLIC
| Name | Biomeme |
| Tagline | Portable PCR labs for biothreat detection and point-of-care diagnostics |
| Headquarters | Philadelphia, United States |
| Founded | 2012 |
| Business Model | Hardware + Software |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Geography | North America |
| Founding Team | Co-Founders (3+) |
| Funding Label | Undisclosed |
Links
PUBLIC
- Website: https://biomeme.com/
- LinkedIn: https://www.linkedin.com/company/biomeme/
- X / Twitter: https://twitter.com/biomemeinc
Executive Summary
PUBLIC
Biomeme has spent the last decade building portable, smartphone-integrated molecular testing platforms, aiming to move PCR diagnostics out of the lab and into the hands of military responders and healthcare workers [Biomeme.com]. The company's thesis is that rapid, field-deployable identification of biological threats and infectious diseases can change outcomes in biodefense and point-of-care medicine, a bet that gained urgency during the pandemic [Biomeme blog]. Founded in 2012, the company's initial product was an iPhone add-on for real-time PCR, which has since evolved into a full suite of hardware, consumables, and software under the Franklin ISP platform [Biomeme blog, TechCrunch, 2013].
The core product is a compact, automated system capable of multiplexed detection of up to 14 biological agents from a single sample, a capability the company markets as lab-grade confirmatory testing for CBRN (chemical, biological, radiological, nuclear) professionals [Biomeme.com]. This hardware-plus-software model targets two distinct sectors: biodefense for military and hazmat teams, and healthcare for host-response mRNA diagnostics [Biomeme.com].
The founding team, led by CEO Max Perelman and EVP of Engineering Marc DeJohn, has guided the company from its consumer-focused origins toward government and medical applications [CBInsights, SignalHire]. Public financials are opaque; no formal funding rounds are disclosed, though investors like Ben Franklin Technology Partners and Mark Cuban Companies are listed, and third-party estimates suggest revenue in the $5-25 million range [Owler].
Over the next 12-18 months, the key indicators to watch are the validation of its military supply claims, any movement toward regulatory clearances for its healthcare diagnostics, and whether the company can transition from a long-standing R&D operation to demonstrating scalable, repeatable commercial contracts. The verdict in Analyst Notes will turn on whether Biomeme can prove its niche in biodefense is defensible and can fund expansion into broader healthcare markets.
Data Accuracy: YELLOW -- Core product claims are confirmed by the company's own materials, but financials, team details, and investor involvement rely on limited or unverified third-party sources.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Business Model | Hardware + Software |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Founding Team | Co-Founders (3+) |
Company Overview
PUBLIC
Biomeme was founded in 2012 in Philadelphia, Pennsylvania, with a founding team of three: Max Perelman, Jesse vanWestrienen, and Marc DeJohn [CBInsights] [SignalHire]. The company's initial vision was to develop consumer-accessible molecular diagnostics, as noted by co-founder Marc DeJohn in a company blog post reflecting on the firm's founding mission [Biomeme blog]. A decade later, the company describes its evolution from a venture focused on consumer use to a provider of advanced testing capabilities for the U.S. military and other professional sectors [Biomeme blog].
The company maintains its headquarters in Philadelphia, having moved to a new office at 401 North Broad Street in recent years [Biomeme blog]. Biomeme operates a BSL-2 laboratory and handles its own software, firmware engineering, and manufacturing from this location [Perplexity Sonar Pro Brief]. Key milestones over its twelve-year history include the development of its first iPhone-compatible PCR device, the expansion into full end-to-end diagnostic solutions, and the reported supply of testing capabilities to the U.S. military [Perplexity Sonar Pro Brief] [Biomeme blog]. The company also marked its 10th anniversary in 2022, highlighting a rebrand and a refined focus on global health and biodefense solutions [Biomeme blog].
Data Accuracy: YELLOW -- Founding year and location are consistent across sources; leadership roles and key milestones are cited from the company's own publications. No independent third-party verification of the military supply claim or detailed timeline was found in the captured research.
Product and Technology
MIXED
Biomeme's core proposition is a hardware and software platform that compresses the capabilities of a molecular biology lab into a portable, field-deployable system. The company's flagship product, the Franklin ISP, is a compact, automated device designed for multiplexed real-time PCR detection, capable of identifying up to 14 biological agents from a single sample [Biomeme.com]. This positions the technology for use cases where speed and mobility are critical, such as military biodefense operations or remote healthcare settings. The system integrates with a smartphone application and cloud-based software, aiming to deliver what the company describes as "lab-grade confirmatory results directly in the field" without specialized laboratory infrastructure [Biomeme.com].
The technology stack is built around proprietary hardware for thermal cycling and fluorescence detection, paired with single-use consumable test strips. The software layer includes a mobile app for running tests and a web-based platform for data analysis and management, suggesting an end-to-end workflow from sample collection to result interpretation [Biomeme.com]. While the company's public materials do not detail the underlying assay chemistry or sensor technology, the product claims center on sensitivity, multiplexing capability, and ease of use for non-specialist operators. Biomeme also offers a separate product line focused on host-response diagnostics, which analyzes mRNA biomarkers to characterize a patient's immune response to infection, targeting point-of-care clinical decisions [Biomeme.com].
Data Accuracy: YELLOW -- Product claims are detailed on the company's website, but technical specifications, performance validation data, and detailed component sourcing are not publicly available.
Market Research
PUBLIC The market for portable molecular diagnostics is being reshaped by a persistent need for rapid, field-deployable biothreat detection and a growing emphasis on decentralized clinical testing.
Third-party market sizing specific to Biomeme's niche of mobile PCR for CBRN defense and point-of-care host response diagnostics is not publicly available. However, analogous public reports illustrate the scale of adjacent sectors. The global point-of-care diagnostics market was valued at approximately $40 billion in 2023 and is projected to grow at a compound annual rate of around 9% [Grand View Research, 2023]. The broader molecular diagnostics segment, which includes PCR and isothermal amplification technologies, represents a multi-billion dollar sub-sector of this total. For biodefense specifically, government spending on CBRN defense remains a critical, though opaque, demand driver, with U.S. Department of Defense budgets for chemical and biological defense programs consistently measured in the hundreds of millions annually [U.S. DoD Budget Documents].
Demand is anchored by two primary, cited tailwinds. First, military and homeland security agencies continue to prioritize rapid, confirmatory identification of biological warfare agents in the field, a need underscored by global geopolitical tensions [Biomeme blog]. Second, the pandemic legacy has accelerated the push for decentralized testing models beyond central labs, particularly for infectious disease surveillance and host-response profiling, which aims to characterize a patient's immune status to guide treatment [Biomeme.com]. The company's stated "One Health" vision also ties it to the growing integration of human, animal, and environmental health monitoring, a trend supported by organizations like the World Health Organization.
Key adjacent markets that serve as both potential expansion vectors and competitive substitutes include traditional lab-based PCR services, which offer higher throughput but lack portability, and rapid antigen tests, which trade some analytical sensitivity for speed and simplicity. The regulatory environment presents a significant macro force; achieving CLIA-waiver status for point-of-care use or navigating the FDA's regulatory pathway for in-vitro diagnostics is a known, resource-intensive hurdle for any company commercializing a novel diagnostic platform.
Data Accuracy: YELLOW -- Market sizing is based on analogous, broad industry reports; specific TAM for the company's niche is not confirmed from independent sources.
Competitive Landscape
MIXED Biomeme occupies a narrow but distinct position in the molecular diagnostics field, competing on portability and rapid, multiplexed detection for specialized, non-traditional lab environments.
Given the confirmed list of named competitors, a comparative analysis is possible. The following table outlines the known competitive set.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Biomeme | Portable PCR/isothermal labs for field-based biodefense and point-of-care host-response diagnostics. | Undisclosed funding; founded 2012. | Focus on multiplexed, smartphone-connected hardware for CBRN and remote health applications. | [Biomeme.com] |
The competitive map is stratified by customer segment and technical approach. In the biodefense and military responder segment, incumbents are large defense contractors and established CBRN equipment suppliers, whose systems are often bulkier and require more specialized training. Biomeme's challenge here is not a direct product-for-product swap, but convincing procurement officers to adopt a new, more agile platform into established protocols. In point-of-care diagnostics for healthcare settings, the landscape is crowded with both large, integrated players like Abbott and Roche, and a host of startups focused on single-analyte, rapid tests. Biomeme's host-response mRNA profiling is a more complex value proposition, competing against standard culture-based diagnostics and newer syndromic PCR panels. Adjacent substitutes include traditional lab send-out services, which remain the default for confirmatory testing in most clinical environments.
Biomeme's defensible edge appears to be its early integration of smartphone-based hardware and a platform designed explicitly for field use, a niche less contested by large diagnostics firms. The company's decade of operation suggests accumulated expertise in ruggedizing PCR technology. A potential regulatory moat exists if its platforms secure specific approvals for field use with military or first-responder agencies, though no such clearances are publicly confirmed. This edge is perishable, however. The core technology of miniaturized PCR is not proprietary in the abstract, and the barrier for a well-funded competitor to develop a similar form factor is not prohibitive. Durability will depend on Biomeme's ability to lock in customers through validated assay panels, software workflows, and established supply contracts with government entities.
The company is most exposed in the broader healthcare diagnostics channel. It lacks the commercial sales infrastructure and clinical trial resources to compete directly for hospital lab contracts against the major IVD companies. Furthermore, startups like Visby Medical, which has pursued a focused, single-use device strategy with clear FDA pathways, may achieve faster commercial adoption in specific infectious disease niches. Biomeme's reliance on a platform that requires user training and sample preparation also makes it vulnerable to competitors developing truly sample-to-answer, disposable cartridge systems that require minimal operator intervention.
The most plausible 18-month competitive scenario hinges on public sector adoption. If Biomeme secures a substantive, multi-year contract with a branch of the U.S. military or a large international health organization for its biowarfare detection suite, it could solidify its niche and generate the revenue needed to fund expansion. In that case, a winner would be Biomeme, while a loser might be a smaller, less diversified competitor like Nuclein, should it be competing for the same contract. Conversely, if the biodefense procurement cycle stalls and a healthcare-focused competitor like Chronus Health or Visby Medical captures significant market share in a high-growth point-of-care segment, Biomeme could find itself boxed into a smaller, slower-moving market without the capital to pivot.
Data Accuracy: YELLOW -- Competitor list is confirmed, but detailed profiles for named rivals are not publicly available. Biomeme's positioning is sourced from its own materials.
Opportunity
PUBLIC
If Biomeme can successfully embed its portable molecular diagnostics as the standard field equipment for military and public health agencies, the company could build a durable, high-margin hardware and consumables business serving a global biosecurity budget that runs into the billions.
The headline opportunity is to become the default field-deployable PCR lab for U.S. and allied biodefense units, a role that would provide a stable, recurring revenue base from instrument placements and high-margin test cartridge sales. The company's own materials state it has already "supplied the U.S. military with advanced testing capabilities" [Biomeme blog, Unknown], providing a critical proof point that its technology meets the rigorous standards of that customer segment. This is not an aspirational market entry; it is a cited deployment that, if expanded, could lead to program-of-record status within defense procurement. The Franklin ISP platform, which the company says can detect up to 14 bio-agents from one sample [Biomeme.com, Unknown], is specifically engineered for this CBRN (chemical, biological, radiological, nuclear) professional use case. Winning this anchor customer creates a referenceable beachhead for adjacent government markets in public health and homeland security.
Growth from this position could follow several concrete paths, each with identifiable catalysts.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Biodefense Standardization | The Franklin ISP becomes a standard-issue item for military CBRN response teams, driving recurring orders for devices and high-volume cartridge contracts. | A multi-year Indefinite Delivery/Indefinite Quantity (IDIQ) contract award from the Department of Defense or a major allied government. | The company cites existing supply to the U.S. military [Biomeme blog, Unknown], demonstrating product acceptance. The global biodefense market is large and driven by persistent threat perception. |
| Public Health Pivot | National public health agencies adopt the platform for distributed pandemic surveillance and point-of-care outbreak testing, moving beyond the military niche. | A new emerging infectious disease threat or a funded initiative like the U.S. BARDA's pandemic preparedness portfolio. | Biomeme's technology is applied to "host response mRNA biomarkers at the point-of-care" [Biomeme.com, Unknown], and the company is part of a $21 million investment for diagnostics in low- and middle-income countries [Biomeme blog, Unknown], showing engagement with the global health ecosystem. |
| One Health Platform | The same core hardware is leveraged for veterinary, agricultural, and environmental monitoring, creating a multi-sector diagnostics platform. | A strategic partnership with a large agribusiness or animal health corporation to co-develop and distribute tests. | The company explicitly frames its vision around the "One Health" concept linking human, animal, and environmental health [Biomeme.com, Unknown], indicating product roadmap alignment. |
Compounding for Biomeme would look like a classic razor-and-blades model fortified by regulatory and training lock-in. Each instrument placement in a military unit or public health lab creates a sunk cost and trained-user base, driving recurring, high-margin revenue from proprietary consumables and assay panels. Over time, a growing installed base of hardware would generate a proprietary dataset on pathogen detection and host responses across geographies, potentially informing future assay development and creating a data moat. The company's move to a new headquarters in Philadelphia suggests an expansion of operational capacity [Biomeme blog, Unknown], a necessary step to support scaling manufacturing and fulfillment if these growth scenarios materialize.
The size of the win, should the Biodefense Standardization scenario play out, can be framed by looking at comparable companies serving government biosecurity budgets. While no direct public competitor exists, large defense contractors with CBRN divisions command significant valuations, and specialized diagnostic companies serving government contracts often trade at revenue multiples reflective of their sticky, high-margin consumables businesses. A more focused comparable might be the acquisition of similar point-of-care molecular diagnostic assets by larger medtech players, which historically occur at substantial premiums. For a company with an estimated $5-25 million in annual revenue [Owler, Unknown], capturing even a single-digit percentage of the multi-billion dollar global CBRN detection market could support a valuation an order of magnitude larger than its current scale (scenario, not a forecast). The opportunity is concentrated and non-consensus, but the cited military engagement provides a tangible thread to pull.
Data Accuracy: YELLOW -- The core opportunity thesis relies on company-stated military engagement and product specs, which are considered primary-source GREEN. The growth scenario plausibility hinges on these statements and the cited involvement in a global health investment. Third-party traction metrics are unverified estimates from Owler.
Sources
PUBLIC
[Biomeme.com] Mobile CBRN Biodefense Solutions & Healthcare Diagnostics | https://biomeme.com/
[Biomeme blog] Meet the New Biomeme: Where Global Health Solutions Are Discovered | https://blog.biomeme.com/why-we-rebranded
[TechCrunch, 2013] Biomeme Wants To Turn Your iOS Device Into A Disease-Detecting Mobile DNA Lab | https://techcrunch.com/2013/08/07/biomeme-wants-to-turn-your-ios-device-into-a-disease-detecting-mobile-dna-lab/?_guc_consent_skip=1588750349
[CBInsights] Biomeme CEO, Founder, Key Executive Team, Board of Directors & Employees | https://www.cbinsights.com/company/biomeme/people
[SignalHire] Biomeme, Inc. Information | SignalHire Company Profile | https://www.signalhire.com/overview/biomeme-inc
[Perplexity Sonar Pro Brief] Biomeme develops mobile molecular diagnostics platforms | (Web-grounded research summary)
[Owler] Biomeme’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News - Owler Company Profile | https://www.owler.com/company/biomeme
[Grand View Research, 2023] Point-of-Care Diagnostics Market Size Report, 2023-2030 | (Market sizing report)
[U.S. DoD Budget Documents] Chemical and Biological Defense Program Annual Report to Congress | (Government budget documents)
[Biomeme blog] Biomeme to Receive Portion of $21 Million Investment for Molecular Diagnostic Testing in LMICs | https://blog.biomeme.com/biomeme-to-receive-portion-of-21-million-investment-for-molecular-diagnostic-testing-in-lmics
[Biomeme blog] Biomeme to Open New Headquarters at Netrality’s 401 North Broad | https://blog.biomeme.com/biomeme-to-open-new-headquarters
Articles about Biomeme
- Biomeme's Portable PCR Lab Aims for the Front Lines — The Philadelphia company, backed by Mark Cuban, has spent a decade shrinking molecular diagnostics for biodefense and point-of-care medicine.